VTL - Vital Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8300
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.8300
Open1.0400
Bid0.0000 x 3100
Ask0.0000 x 2200
Day's Range0.7751 - 1.1700
52 Week Range0.1510 - 9.7500
Volume86,513,466
Avg. Volume8,402,036
Market Cap879,169
Beta (3Y Monthly)1.72
PE Ratio (TTM)N/A
EPS (TTM)-0.8570
Earnings DateOct 23, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.50
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

    SAN DIEGO and PLANEGG-MARTINSRIED, Germany, April 12, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq:IMUX), today announced the completion of its stock-for-stock exchange transaction with Vital Therapies, Inc. (Nasdaq: VTL, through April 12, 2019). The company has been renamed Immunic, Inc. and its common stock is expected to commence trading on The Nasdaq Capital Market under the ticker symbol "IMUX" on April 15, 2019.

  • GlobeNewswire9 days ago

    Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019

    Vital Therapies, Inc. (Nasdaq:  VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to facilitate the closing of the Company’s transaction with Immunic AG. As previously announced, the transaction has been approved by the stockholders of the Company and is expected to be consummated by mid-April.

  • ACCESSWIRE10 days ago

    How Might the Immunic Combination with Vital Therapies Impact Investors

    NEW YORK, NY / ACCESSWIRE / April 10, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Vital Therapies, Inc. (VTL) is a biotherapeutic company, focused on developing cell-based therapies for the treatment of acute forms of liver failure. Vital Therapies announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held Friday. On Friday, April 5, 2019, VTL shares opened at $.26 per share and reached a high of $.70 per share before closing at $.51 on traded volume of 154.5 million shares.

  • Benzinga15 days ago

    The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...

  • GlobeNewswire15 days ago

    Vital Therapies, Inc. Announces Stockholder Approval of Business Combination with Immunic AG

    Vital Therapies, Inc. (Nasdaq:  VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with Immunic AG at a special meeting of Vital Therapies stockholders held earlier today.  Approximately 98.82% of the shares voted at the special stockholder meeting voted in favor of the Exchange Agreement proposal, with each of the other related proposals also receiving sufficient votes for approval. “We truly appreciate the support we have received from our stockholders for this transformational combination with Immunic,” said Duane Nash, President and Chief Executive Officer of Vital Therapies.

  • GlobeNewswire24 days ago

    Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG

    Vital Therapies, Inc. (VTL) would like to thank its stockholders for their support of the proposed business combination with Immunic AG and remind those stockholders that have not yet voted to vote without delay “FOR” the business combination and the other proposals in the Company’s proxy statement/prospectus for the special meeting of its stockholders to be held on April 4, 2019 at 9:00 a.m. Pacific Time. “The overwhelming majority of Vital Therapies stockholders who have submitted their votes have voted in favor of the transaction.  However, more votes are needed to meet the required threshold for the business combination to be completed,” stated Duane Nash, President and Chief Executive Officer of Vital Therapies.

  • GlobeNewswire26 days ago

    Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Vital Therapies Stockholders Vote “FOR” the Proposed Business Transaction With Immunic AG and All the Related Proposals

    Vital Therapies, Inc. (VTL) announced today that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that Vital Therapies stockholders vote “FOR” the proposed business combination with Immunic AG and the related proposals in the Company’s proxy statement/prospectus for the special meeting of its stockholders to be held on April 4, 2019 at 9:00 a.m. Pacific Time.

  • GlobeNewswire2 months ago

    Vital Therapies Announces 2018 Financial Results

    Vital Therapies, Inc. (VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the year ended December 31, 2018. On January 6, 2019, we entered into an exchange agreement (the “Exchange Agreement”), with Immunic AG, or Immunic, and all of the current shareholders of Immunic.  Under this agreement, all Immunic shareholders will exchange all of their Immunic shares for shares of our common stock, with the result of Immunic becoming a wholly-owned subsidiary of Vital Therapies (the “Transaction”).  Concurrently, Immunic’s shareholders entered into an agreement with Immunic, under which, subject to the terms and conditions of such agreement, they will invest an aggregate amount of approximately €26.7 million, or US $30.5 million, in Immunic prior to the consummation of the Transaction.

  • PR Newswire2 months ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Vital Therapies, Inc. - VTL

    NEW YORK , Feb. 26, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • GlobeNewswire3 months ago

    Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

    SAN DIEGO and PLANEGG-MARTINSRIED, Germany, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL), and Immunic AG (Immunic), a private clinical-stage biotechnology company in Planegg-Martinsried, Germany, today announced that they have entered into a definitive agreement under which Vital Therapies is expected to acquire all of the outstanding shares in Immunic in exchange for newly issued shares of Vital Therapies in an all-stock transaction. The company will focus on advancing Immunic‘s pipeline of novel and potentially transformative treatments for chronic inflammatory and autoimmune diseases.

  • Associated Press5 months ago

    Vital Therapies: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 28 cents. In the final minutes of trading on Wednesday, the company's shares hit 35 cents. A year ago, they were trading at $5.80. ...

  • GlobeNewswire5 months ago

    Vital Therapies Announces Third Quarter 2018 Financial Results

    SAN DIEGO, Nov. 07, 2018 -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company that has been developing ELAD®, a cell-based therapy targeting the treatment of acute.

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies

    NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Tonix Pharmaceuticals and Vital Therapies Inc. both saw big gains in Wednesday’s session despite either company releasing any news nor there being any catalyst to set shares off. Tonix was expected to have presented this week at the MicroCap Conference. Tonix Pharmaceuticals Holding Corp. shares closed up 17.80% on Wednesday with an additional gain of 5.04% in after-hours trading.

  • Who Are Vital Therapies Inc’s (NASDAQ:VTL) Major Shareholders?
    Simply Wall St.7 months ago

    Who Are Vital Therapies Inc’s (NASDAQ:VTL) Major Shareholders?

    Every investor in Vital Therapies Inc (NASDAQ:VTL) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...

  • Is the Options Market Predicting a Spike in Vital Therapies (VTL) Stock?
    Zacks7 months ago

    Is the Options Market Predicting a Spike in Vital Therapies (VTL) Stock?

    Investors need to pay close attention to Vital Therapies (VTL) stock based on the movements in the options market lately.

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Bausch Health Companies and Vital Therapies

    NEW YORK, NY / ACCESSWIRE / September 13, 2018 / Bausch Health Companies together with Salix's licensors Cedars-Sinai Medical Center and Alfasigma SpA resolve the outstanding intellectual property litigation ...

  • 3 Biotech Stocks That Could Double Your Money
    Motley Fool7 months ago

    3 Biotech Stocks That Could Double Your Money

    Wall Street's pinned high hopes on these four biotech stocks.

  • Associated Press8 months ago

    Vital Therapies: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 30 cents per share. Vital Therapies shares have increased 45 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares ...

  • Benzinga8 months ago

    William Blair Upgrades Vital Therapies Ahead Of September Liver Failure Data

    Top-line data from Vital Therapies’ study on the treatment of liver failure is expected to be released in September, Xu said in a Monday note. About 60 percent of sAAH patients are younger patients without renal failure or severe coagulopathy, which are part of the main inclusion criteria for VTL-308.